About Us
- Who We Are
- Our Leadership
- Local & State Offices
- Planned Parenthood Global
- Newsroom
- Advisory Boards & Initiatives
- Jobs & Volunteering
- Annual Report
- About This Site
- Contact Us
Planned Parenthood Applauds FDA Approval of Lybrel
NEW YORK CITY — Planned Parenthood Federation of America (PPFA) applauded the U.S. Food and Drug Administration (FDA) approval today of Lybrel, the only pill designed to be taken daily without placebo reminder pills, 365 days a year. When used consistently and correctly, Lybrel completely suppresses the menstrual cycle, is up to 99.7 percent effective at preventing unintended pregnancy, and offers many women relief from menstrual cramps, headaches, and other discomforts associated with periods.
PPFA Vice President for Medical Affairs Vanessa Cullins, M.D., issued the following statement about Lybrel:
"FDA approval of Lybrel is great news for women who want or need to safely suppress their menstrual cycle, and now they have the convenience of a full year's birth control prescription to do it.
"At Planned Parenthood we know every woman's birth control needs are different, and the best methods are those that fit a woman's lifestyle and meet her needs — including safety, effectiveness, affordability, and reversibility. Lybrel is a good hormonal birth control option for women who don’t want to have a period every month. We are pleased to see a new, safe, and effective birth control option for women on the market."
Planned Parenthood is the nation’s leading sexual and reproductive health care provider and advocate. We believe that everyone has the right to choose when or whether to have a child, and that every child should be wanted and loved. Planned Parenthood affiliates operate nearly 800 health centers nationwide, providing medical services and sexuality education for millions of women, men, and teenagers each year. We also work with allies worldwide to ensure that all women and men have the right and the means to meet their sexual and reproductive health care needs.
